Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer CenterGlobeNewsWire • 12/01/20
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent GlioblastomaGlobeNewsWire • 11/19/20
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial UpdateGlobeNewsWire • 11/13/20
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma TrialGlobeNewsWire • 10/29/20
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/23/20
Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsGlobeNewsWire • 10/22/20
Plus Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on October 22, 2020GlobeNewsWire • 10/14/20
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual MeetingGlobeNewsWire • 10/01/20
Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma TreatmentGlobeNewsWire • 09/15/20
Plus Therapeutics, Inc. to Present at the 9th Annual Gateway Conference on September 10, 2020GlobeNewsWire • 09/03/20
Plus Therapeutics, Inc.(PSTV) CEO Marc Hedrick on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Plus Therapeutics To Report Second Quarter Fiscal Year 2020 Financial Results And Corporate Update on August 10, 2020GlobeNewsWire • 08/03/20
Plus Therapeutics Completes Fifth Dose Escalation Cohort of the ReSPECT™ Glioblastoma Clinical Trial and Expands Trial SitesGlobeNewsWire • 07/28/20
Plus Therapeutics to Present at the YAFO Access China Partnering Conference on July 30, 2020GlobeNewsWire • 07/23/20
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20
Plus Therapeutics Announces Closing of Agreement To License Novel Oncology PlatformGlobeNewsWire • 05/11/20